Recursion Pharmaceuticals(us:RXRX)
5.09
-3.78%
Updated on 2025-04-02
Open:5.32
Close:5.09
High:5.34
Low:5.00
Prev Close:5.29
Volume:16.98M
Turnover:87.30M
Turnover Ratio:4.22%
Shares:401.99M
MarketCap:2.05B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 8 | 11955459 | 4.45% | 4 | 3 | 0 |
| 2024-03-31 | 255 | 201922806 | 85.02% | 66 | 85 | 69 |
| 2023-12-31 | 228 | 198781793 | 84.85% | 40 | 69 | 82 |
| 2023-09-30 | 206 | 148663771 | 68.73% | 55 | 72 | 57 |
| 2023-06-30 | 179 | 124567389 | 60.25% | 26 | 58 | 68 |
| 2023-03-31 | 166 | 121721258 | 63.32% | 26 | 55 | 44 |
| 2022-12-31 | 162 | 123700321 | 64.76% | 20 | 62 | 49 |
| 2022-09-30 | 154 | 109283729 | 62.78% | 23 | 62 | 40 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Ark Investment Management Llc | 28142918 | 10.02% | 3555357 | 14.46% |
| 2024-06-30 | Baillie Gifford & Co | 26589936 | 9.46% | 2522132 | 10.48% |
| 2024-06-30 | Vanguard Group Inc | 21556546 | 7.67% | 5541782 | 34.60% |
| 2024-06-30 | Blackrock Inc. | 17310162 | 6.16% | 4989127 | 40.49% |
| 2024-06-30 | Ra Capital Management, L.P. | 15384615 | 5.48% | 15384615 | |
| 2024-06-30 | Mubadala Investment Co Pjsc | 12985927 | 4.62% | 0 | |
| 2024-06-30 | Kinnevik Ab (Publ) | 11905668 | 4.24% | 1500000 | 14.41% |
| 2024-06-30 | Sumitomo Mitsui Trust Holdings, Inc. | 9987030 | 3.55% | -375773 | -3.63% |
| 2024-06-30 | Nikko Asset Management Americas, Inc. | 9934491 | 3.54% | -428312 | -4.13% |
| 2024-06-30 | State Street Corp | 8749587 | 3.11% | -1602769 | -15.48% |
About
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
Address:41 South Rio Grande Street
Website:http://www.recursion.com
Market Movers